Nové moznosti I lécby glioblastoma multiforme
[New therapeutic options in therapy of glioblastoma multiforme]
Jazyk čeština Země Česko Médium print
Typ dokumentu anglický abstrakt, časopisecké články, práce podpořená grantem, přehledy
PubMed
21351415
- MeSH
- glioblastom terapie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- nádory mozku terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Glioblastoma multiforme is one of the most aggressive malignant brain tumours with limited therapeutics options. Standard therapy is maximal surgical resection and adjuvant concurrent chemo-radiotherapy and maintenance therapy with temozolomide. This approach improves median and 5-year survival in comparison with postsurgical radiotherapy alone. Additional predictive and prognostic biomarkers are necessary, especially due to the development of targeted therapy--antibodies and tyrosine kinase inhibitors. These new therapeutic approaches are under intensive investigation. The most promising data currently available are for anti-angiogenic therapies, such as bevacizumab and cediranib. This review presents a summary of the possible role of targeted therapy in the treatment of glioblastoma multiforme.